Lexicon Pharmaceuticals (LXRX) : 5 analysts are covering Lexicon Pharmaceuticals (LXRX) and their average rating on the stock is 2.4, which is read as a Buy. 2 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 5, which recommends a Strong Sell affirms that they expect a large upside in the stock from the current levels. 1 more analyst has given the stock a Sell recommendation. A total of 2 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
Lexicon Pharmaceuticals (LXRX) has been rated by 4 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $30 and the lowest price target forecast is $11. The average forecast of all the analysts is $20.38 and the expected standard deviation is $8.77.
For the current week, the company shares have a recommendation consensus of Buy.
Lexicon Pharmaceuticals (NASDAQ:LXRX): During Tuesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $14.96 and $14.75 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $15.04. The buying momentum continued till the end and the stock did not give up its gains. It closed at $14.85, notching a gain of 0.68% for the day. The total traded volume was 1,008,865 . The stock had closed at $14.75 on the previous day.
Lexicon Pharmaceuticals, Inc. (Lexicon) is a biopharmaceutical company. The Company is focused on the development of treatments for human disease. The Company is engaged in the development of two drug candidates: telotristat etiprate (LX1032) and sotagliflozin (LX4211). The Companys telotristat etiprate is an orally delivered small molecule drug candidate, as a treatment for carcinoid syndrome. It has completed two Phase II clinical trials and is conducting a single Phase III clinical trial of telotristat etiprate in carcinoid syndrome patients. The Companys sotagliflozin is an orally delivered small molecule drug candidate, as a treatment for type 1 and type 2 diabetes. The Company has completed two Phase II clinical trials of sotagliflozin in type 2 diabetes patients and an additional clinical trial of sotagliflozin in type 2 diabetes patients with renal impairment. It has also completed a Phase II clinical trial of sotagliflozin in type 1 diabetes patients.